Ricky Turgeon PharmD
@Ricky_Turgeon
Followers
2K
Following
5K
Media
215
Statuses
4K
CV Pharmacist-Researcher, Assistant Prof @ubcpharmacy EBM & shared decision making enthusiast, all-around nerd. Slowly moving to https://t.co/kTfKXf3X6E
Vancouver, British Columbia
Joined March 2014
How to Critically Appraise a Trial in 10 Minutes: The NERDCAT Approach: The Tweetorial 1/.
7
100
336
RT @wbaker0531: I was honored to co-lead this effort with Alex Chan and a wonderful groups of authors. Give it a read. @UConnPharmacy.
0
3
0
RT @kaulcsmc: @djc795 @DFCapodanno @TCTMD @PCRonline Attributes of ideal NI trial:.90-95% power.Margin fixed as relative difference, RR 1.5….
0
1
0
RT @JCardFail: Is there finally a verdict on MRAs in HFmrEF/HFpEF? . This recent #JCFIgnite! re-examines the data and finds that both ste….
0
7
0
RT @CSHPBCBranch: We are inviting you to join CSHP and the Canadian Cardiovascular Pharmacists Network this Saturday February 1, 2025 at 10….
0
1
0
RT @ArdenBarry: Join me at the 2nd @CCPNRx @CSHP_SCPH CVD Symposium--focusing on ASCVD--on Feb 1 (to kick off Heart Month). The program is….
ccs.ca
Join CSHP and the Canadian Cardiovascular Pharmacists Network on February 1 for this one-day virtual event delivering an in-depth look at ASCVD. Hear from experts covering diagnosis, assessment,...
0
2
0
RT @drbennisahmed: Evaluation of PHARM-HF, a pharmacist-led heart failure medication titration clinic: A pre-post study. Uptake of GDMT sig….
0
4
0
RT @CSHP_SCPH: ❣️ Elevate Patient Care with CSHP and @CCPNrx! . Gain the tools and insights to deliver exceptional care for patients with A….
0
1
0
RT @wbaker0531: More data supporting the role of pharmacists in HF and associated conditions. @accpcardprn.
0
3
0
RT @Mina__T: Watch our updated top 15 outpatient drug purchases in 🇨🇦 From our updated forecast paper! https://t.co….
0
1
0
RT @CraigBaird: When it comes to the Christmas season in French Canada, one dish that is always loved is Tourtière. It is a delicious dish,….
0
225
0
Going to #AHA24? Come talk to @BlairMacPharmD about our latest modeling study of pharmacotherapy for heart failure with reduced ejection fraction, this time looking at 1-year efficacy/safety of different quadruple therapy sequencing strategies:
0
1
5
RT @CCPNRx: Join us virtually at the 23rd Annual CCPN Western Symposium on Saturday, November 23! Agenda at Registe….
eventbrite.ca
Join us for the CCPN's 23rd Annual Western Symposium, where we'll discuss the latest in cardiovascular disease!
0
3
0
If you liked yesterday's @CMAJ paper on heart failure sequencing strategies, wait until you see what @BlairMacPharmD's cooking up next as part of his CIHR HSI fellowship - 'Evaluation of Models of Care for HFrEF Through the Use of a Microsimulation Model'.
The new cohort of the Health System Impact Fellowship is here! 🎉 45 talented researchers will work with 35 health organizations nationwide to drive innovation and tackle Canada's most pressing health issues. #CIHR_ImpactFellows
0
2
10
RT @CIHR_IRSC: The new cohort of the Health System Impact Fellowship is here! 🎉 45 talented researchers will work with 35 health organizati….
0
13
0
RT @gcfmd: Simultaneous initiation of the 4 standard HFrEF medications with biweekly adjustment provided the highest cost utility compared….
0
8
0
RT @CMAJ: Pharmacotherapy in heart failure:.Simultaneous initiation of the 4 standard heart failure medications with biweekly adjustment pr….
cmaj.ca
Background: Standard pharmacotherapy for patients with heart failure with reduced ejection fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a β-blocker, a...
0
2
0
@CMAJ The first highlighted sentence from the editorial sums up the results nicely; the second & third inject some of the realities of practice & reasons to look at some of the other profiles modeled in this study as well
2
2
6